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Abstract
Background: Imatinib and second-generation tyrosine kinase inhibitors (TKIs) nilotinib and dasatinib have statistically
significantly improved the life expectancy of chronic myeloid leukemia (CML) patients; however, resistance to TKIs remains a
major clinical challenge. Although ponatinib, a third-generation TKI, improves outcomes for patients with BCR-ABL-
dependent mechanisms of resistance, including the T315I mutation, a proportion of patients may have or develop BCR-
ABL-independent resistance and fail ponatinib treatment. By modeling ponatinib resistance and testing samples from these
CML patients, it is hoped that an alternative drug target can be identified and inhibited with a novel compound.
Methods: Two CML cell lines with acquired BCR-ABL-independent resistance were generated following culture in ponatinib.
RNA sequencing and gene ontology (GO) enrichment were used to detect aberrant transcriptional response in ponatinib-
resistant cells. A validated oncogene drug library was used to identify US Food and Drug Administration–approved drugs with
activity against TKI-resistant cells. Validation was performed using bone marrow (BM)–derived cells from TKI-resistant
patients (n¼4) and a human xenograft mouse model (n¼4–6 mice per group). All statistical tests were two-sided.
Results: We show that ponatinib-resistant CML cells can acquire BCR-ABL-independent resistance mediated through alterna-
tive activation of mTOR. Following transcriptomic analysis and drug screening, we highlight mTOR inhibition as an alterna-
tive therapeutic approach in TKI-resistant CML cells. Additionally, we show that catalytic mTOR inhibitors induce autophagy
and demonstrate that genetic or pharmacological inhibition of autophagy sensitizes ponatinib-resistant CML cells to death
induced by mTOR inhibition in vitro (% number of colonies of control[SD], NVP-BEZ235 vs NVP-BEZ235þHCQ: 45.0[17.9]%
vs 24.0[8.4]%, P ¼ .002) and in vivo (median survival of NVP-BEZ235- vs NVP-BEZ235þHCQ-treated mice: 38.5 days vs 47.0 days,
P ¼ .04).
Conclusion: Combined mTOR and autophagy inhibition may provide an attractive approach to target BCR-ABL-independent
mechanism of resistance.
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Chronic myeloid leukemia (CML) is caused by a reciprocal translo-
cation giving rise to the Philadelphia (Ph) chromosome within a
hemopoietic stem cell (1). This leads to transcription/translation
of BCR-ABL, a constitutively active tyrosine kinase (2). CML usually
presents in a chronic phase (CP), before progressing to accelerated
phase (AP) and terminal blast crisis (BC) if left untreated. Imatinib
has statistically significantly improved life expectancy by inducing
cytogenetic and molecular responses in the majority of patients in
CP (3). However, the pathway to “cure” has been tempered by drug
intolerance, insensitivity of CML stem cells to TKIs (4–7), and drug
resistance (8,9).
The mechanisms of drug resistance have been extensively
investigated and can be classified as BCR-ABL dependent or inde-
pendent. It is known that approximately 50% of patients who
relapse on imatinib have mutations within the ABL kinase domain,
affecting imatinib binding within the kinase pocket (10). Dasatinib,
nilotinib, and/or bosutinib have activity against the majority of
imatinib-resistant mutants, except T315I (11). Although the devel-
opment of a TKI active against the T315I mutant has proven chal-
lenging, ponatinib (AP24534), a third-generation TKI, has activity
against T315I in vitro (12) and in patients (13,14). Ponatinib was
tested in the PACE clinical trial in patients with the T315I mutation
or who are resistant/intolerant to either dasatinib or nilotinib.
Findings from PACE show that major molecular response (MMR) is
achieved in 56% of CP patients with the T315I mutation (14),
although a proportion of patients will ultimately develop or be pro-
ven to have ponatinib-resistant disease.
Patients whose disease fails multiple TKI treatments with-
out having ABL kinase domain mutations predominantly repre-
sent a population with BCR-ABL-independent mechanisms of
resistance. For this group of patients, the treatment options are
very limited, and only 27% of “resistant/intolerant” patients
achieved MMR in the PACE trial (14). Although much less is
known about BCR-ABL-independent resistance, a recent genetic
study has shown that it can vary between individuals, often
suggesting re-activation of signaling pathways involved in CML
pathogenesis (15). Additionally, studies have shown that
increased FGF2 in the BM (16) or activation of LYN (17,18) may
be responsible for the survival of cells following BCR-ABL inhibi-
tion. However, ponatinib, which has activity against FGF recep-
tor and LYN kinase (12), has been shown to overcome FGF2-
mediated resistance in CML patients without kinase domain
mutations (16) and to be effective against many imatinib-
resistant CML cell lines (19), highlighting the importance of
using ponatinib as the TKI of choice for investigation of
acquired BCR-ABL-independent resistance in CML.
The goals of the current study were to examine what drives
BCR-ABL-independent resistance and identify clinically relevant
oncology compounds with activity against ponatinib-resistant cells.
Methods
Transplantation Experiments
Human KCL22Pon-Res cells, labeled with lentiviral firefly lucifer-
ase, were transplanted via tail vein injection into eight- to
12-week-old female NSG mice (four to six mice were assigned
per drug arm per experiment). For in vivo treatment, after one
week, the mice were treated with vehicle control, HCQ, NVP-
BEZ235, or the combination of NVP-BEZ235/HCQ for four to five
weeks.
Ethics Statements
CML and normal samples (n ¼ 4 and n ¼ 5, respectively)
required informed consent in accordance with the Declaration
of Helsinki and approval of the National Health Service (NHS)
Greater Glasgow Institutional Review Board. Ethical approval
has been given to the research tissue bank (REC 15/WS/0077)
and for using surplus human tissue in research (REC 10/S0704/
60). Animal work was carried out with ethical approval from the
University of Glasgow under the Animal (Scientific Procedures)
Act 1986. Animal experiments were performed in accordance
with Home Office regulations under an approved project license
(PPL No: 60/4492).
Gene Ontology Term Enrichment Analysis
Gene ontology (GO) term enrichment analysis was carried out
using the GO.db (v3.2.2) and GOstats (v2.36.0) Bioconductor
libraries in R; P values were generated using a hypergeometric
test and adjusted for multiple testing (20).
Statistical Analysis
Error bars represent SD. Statistical analyses were performed
using the two-tailed Student’s t test or Gehan-Breslow
Wilcoxon test. A P value of .05 or less was taken to be statisti-
cally significant.
Detailed information on all other methods can be found in
the Supplementary Material (available online).
Results
Cellular Modeling of BCR-ABL-Independent Mechanisms
of Resistance
Imatinib-resistant cell lines are often sensitive to more
potent second-generation TKIs and/or ponatinib and are
therefore not an ideal model to investigate acquired resist-
ance to all available TKIs (Supplementary Figure 1, A–C,
available online). Hence, we aimed to develop a ponatinib-
resistant cell line with acquired BCR-ABL-independent resist-
ance. KCL22 cells (human myeloid BC CML cell line) were grown
in increasing concentrations of ponatinib for a prolonged period.
Ponatinib-resistant (KCL22Pon-Res) clones continued to proliferate
when exposed to 100 nM ponatinib (Figure 1A). Sequencing of the
BCR-ABL kinase domain showed no kinase domain mutations
(data not shown). Measuring tyrosine 207 phosphorylation of
CRKL, a direct BCR-ABL substrate, revealed that BCR-ABL activity
was inhibited to similar levels as in KCL22T315I and parental
KCL22 (Figure 1B).
Transcriptional Response and mTORC1 Activity
Following BCR-ABL Inhibition in KCL22Pon-Res Cells
To investigate the potential mechanism(s) of resistance in
KCL22Pon-Res cells, parental KCL22 and KCL22Pon-Res cells were
treated with ponatinib to fully switch off BCR-ABL signaling
(Supplementary Figure 2A, available online), and RNA was
harvested for transcriptomic analysis. Of the 5736 gene tran-
scripts that met the necessary expression thresholds in the
RNA sequencing (RNA-seq) experiment, only 250 were
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differently expressed between the two cell lines
(Supplementary Figure 2B, available online). Pathway enrich-
ment analysis highlighted 42 potentially deregulated path-
ways (Supplementary Figure 2C, available online). More
strikingly, while 1661 were differentially expressed following
ponatinib-mediated BCR-ABL inhibition in the parental KCL22
cells, the same treatment had virtually no effect on the tran-
scriptome of KCL22Pon-Res cells (Figure 2, A and B). There was
no correlation (r ¼ 0.60) between the two cell lines in the
transcriptional response of the 5736 genes to ponatinib
(Figure 2C). This suggested that signaling pathways down-
stream of BCR-ABL (and normally inhibited by TKIs) remained
active following BCR-ABL inhibition in KCL22Pon-Res cells.
To investigate further the mechanism(s) of resistance of
KCL22Pon-Res cells, parental KCL22, KCL22T315I, and KCL22Pon-Res
cells were treated with dasatinib or ponatinib, and inhibition of
targets downstream of BCR-ABL was measured. This revealed
inhibition of CRKL and STAT5 phosphorylation, indicative of
complete inhibition of BCR-ABL, but sustained phosphorylation
of the translation regulator ribosomal protein S6 (RPS6) indi-
cated activation of mTOR complex 1 (mTORC1) (21), a common
downstream node on which multiple oncogenic signaling path-
ways converge (Figure 2D; Supplementary Figure 2A, available
online).
Drug Repurposing Screen in KCL22Pon-Res Cells
We next aimed to identify approved anticancer drug(s) with effi-
cacy against TKI-resistant cells. We performed a screen using a
validated oncogene drug library of 119 approved oncology drugs
(Supplementary Table 1, available online). KCL22Pon-Res cells
were cultured alone or in combination with 100 nM ponatinib.
The effect of additional drug exposure on cell survival was
measured (omacetaxine mepesuccinate, a US Food and Drug
Administration (FDA)–approved but nonselective and toxic
inhibitor of total protein biosynthesis [22] was used as a control
drug). This approach identified 36 drugs that were more effec-
tive in inhibiting proliferation of KCL22Pon-Res cells when com-
pared with all BCR-ABL-targeting TKIs tested (Supplementary
Figure 3A, available online). Identified drugs included various
conventional chemotherapeutic drugs and more specific kinase
inhibitors. Comparison of drug sensitivity between
parental KCL22 and KCL22Pon-Res cells confirmed resistance of
KCL22Pon-Res cells to all FDA-approved BCR-ABL-targeting TKIs
and demonstrated that all other drugs that are effective against
parental KCL22 cells at 1 mM retained their activity against
KCL22Pon-Res cells (Figure 3A). Comparison of untreated and
KCL22Pon-Res cells grown in the presence of 100 nM ponatinib
showed that single-agent treatment was similarly effective as
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Figure 1. Proliferation of ponatinib-resistant chronic myeloid leukemia cells in the absence of BCR-ABL kinase activity. KCL22 (wild-type BCR-ABL), KCL22T315I, and
KCL22Pon-Res cells were cultured with or without (Untr) increasing concentrations of ponatinib and 150 nM dasatinib. Proliferation was measured by cell counting using
a glass hemocytometer following 24, 48, and 72 hours of drug treatment, and IC50 values were calculated using GraphPad Prism software (A). To assess for BCR-ABL
activity, the levels of phosphorylation of CRKL were measured by immunoblot following four hours of drug treatment at varying concentrations of ponatinib and 150
nM dasatinib (B). Error bars ¼ SD. Two independent experiments were performed in triplicate. Untr ¼ untreated.
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when combined with complete BCR-ABL inhibition (Figure 3B).
Subsequent target association analysis enriched for and high-
lighted microtubule, proteasome, and allosteric mTORC1 inhibi-
tors (Supplementary Figure 3B, available online). However,
these microtubule and proteasome inhibitors have known tox-
icities in the clinic. With IC50 levels for everolimus, sirolimus,
and temsirolimus all below 200 nM (indicating on-target effect),
regardless of whether used alone or in combination with pona-
tinib (Supplementary Figure 3, A–C, available online), we
decided to focus our subsequent work on mTOR as a potential
target for TKI resistance. This decision was also supported by
the data shown in Figure 2B and Supplementary Figure 2 (avail-
able online), which suggest that sustained mTORC1 activity may
support survival of KCL22Pon-Res cells following TKI treatment.
Sensitivity of KCL22Pon-Res and TKI-Resistant Primary
CML Cells to Catalytic mTOR Inhibitors
To date, sirolimus (rapamycin) and rapamycin analogues (allos-
teric mTORC1 inhibitors) (Supplementary Table 2, available
online) have only shown modest efficacy in clinical trials (23).
This is believed to be because they are incomplete, substrate-
selective mTORC1 inhibitors (24). However, with the develop-
ment of catalytic mTOR inhibitors, it is still hoped that mTOR
represents a druggable target in malignancies driven by activa-
tion of the mTOR pathway. To confirm deeper mTORC1 inhibi-
tion with catalytic mTOR inhibitors, KCL22Pon-Res cells were
treated with PI-103 and its derivative NVP-BEZ235 (which inhibit
both mTORC1 and mTORC2 and have activity against all PI3K
isoforms [25,26]) and compared with rapamycin (Figure 4A).
In line with previous studies, rapamycin had little effect on
phosphorylation of 4E-BP1, whereas PI-103 and NVP-BEZ235
(using IC50 concentrations) led to reduction in 4E-BP1 phos-
phorylation, demonstrating more potent mTORC1 inhibition
(Figure 4B). Seventy-two hours of drug treatment led to modest
induction of apoptosis by rapamycin, with more extensive and
statistically significant apoptosis observed following NVP-
BEZ235 treatment (44.2[9.6]%, P ¼ .02), whereas TKIs had no
effect (Figure 4C). Similar effects were seen in colony forming
cell (CFC) assay (data not shown). To test if these findings would
replicate using different BCR-ABL-positive cell lines, we gener-
ated ponatinib-resistant BaF3 cells (BaF3Pon-Res), which were
also highly sensitive to NVP-BEZ235, showing that sensitivity of
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Figure 2. Transcriptional response and mTORC1 activity in ponatinib-resistant cells following BCR-ABL inhibition. KCL22 and KCL22Pon-Res cells were cultured with or
without 100 nM ponatinib for 24 hours and RNA harvested for RNA-seq. A) The transcriptional response of KCL22 and KCL22Pon-Res cells is represented by Volcano plots
(up- and downregulation are indicated by magenta and green, respectively; light and dark colors correspond to q-value thresholds of 0.05 and 0.01, respectively; statis-
tically nonsignificant changes are colored gray). B) A proportional Venn diagram represents the overlap in statistically significant response to ponatinib (q  0.05) in
both cell lines (4073 refers to the number of genes not changed). C) A direct comparison of the transcriptional response of all genes in both cell lines; identical expres-
sion is shown by the red line; the true linear relationship is indicated by the blue line. D) KCL22, KCL22T315I, and KCL22Pon-Res cells were cultured 6 150 nM dasatinib or
100 nM ponatinib. Phosphorylation of CRKL, STAT5, and RPS6 was measured after 24 hours of drug treatment.A
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ponatinib-resistant cells to mTOR inhibition is not restricted to
the KCL22Pon-Res cell line (Supplementary Figure 4A, available
online). We then examined whether ponatinib-mediated BCR-
ABL inhibition further enhanced the effect of NVP-BEZ235. In
line with Figure 3B and Supplementary Figure 3C (available
online), no increase was observed following ponatinib and NVP-
BEZ235 combination over NVP-BEZ235 alone when apoptosis or
CFC was measured (Supplementary Figure 4, B and C, available
online).
Encouraged by these results and to translate our findings
closer to the clinic, we compared the effect of ponatinib with
various catalytic mTOR inhibitors on available progenitor cells
derived from the BM of a patient who had failed to achieve com-
plete cytogenetic response following first-, second-, and third-
generation TKI treatments. Importantly, while ponatinib was
ineffective, the catalytic mTOR inhibitors NVP-BEZ235 (26),
Gedatolisib (27,28), Apitolisib (29,30), VS-5584 (31), and AZD8055
(32) all induced apoptosis over and above the ponatinib-treated
arm (Supplementary Figure 5, available online).
To further understand the mechanism by which NVP-
BEZ235 induced death, we performed RNA-seq on parental
KCL22 and KCL22Pon-Res. Strikingly, while ponatinib had no
effect on gene transcription in KCL22Pon-Res cells (Figure 2, A and
B), NVP-BEZ235 was sufficient to induce transcriptional changes
on the same scale as ponatinib-treated parental KCL22 cells
(Figure 4D, compare with Figure 2A). Further analysis showed
that the majority of gene changes following ponatinib and
NVP-BEZ235 combination treatment were accounted for in the
NVP-BEZ235 single arm (Figure 4E). Additionally, comparison of
transcriptional changes in ponatinib-treated KCL22 cells and
NVP-BEZ235-treated KCL22Pon-Res cells showed a high correla-
tion (r ¼ 0.78) in transcriptional effect, with the majority (80%)
of statistically significant (q  0.05) changes following BCR-ABL
inhibition in the parental cells also occurring in NVP-BEZ235-
treated KCL22Pon-Res cells (Figure 4, F and G). Substantial overlap
in transcriptional changes was also shown when NVP-BEZ235-
treated KCL22 cells were included in the analysis, demonstrat-
ing that targeting mTOR downstream of BCR-ABL rescues the
impaired transcriptional response following BCR-ABL inhibition
in TKI-resistant cells (Supplementary Figure 6A, available
online). GO enrichment analysis of the differentially expressed
genes showed that ponatinib treatment in KCL22 and NVP-
BEZ235 treatment in KCL22Pon-Res cells affected genes involved
in the execution of apoptosis and DNA repair (Supplementary
Figure 6Bi, available online). A parallel analysis demonstrated
that NVP-BEZ235 treatment was additionally associated with
changes in protein synthesis/mRNA translation
(Supplementary Figure 6Bii, available online).
The Effect of Catalytic mTORC1 Inhibition on Autophagy
in KCL22Pon-Res Cells
mTORC1 not only regulates mRNA translation, but is also the
master regulator of autophagy (macro-autophagy) (33,34). To
assess autophagy flow, we generated KCL22Pon-Res cell lines sta-
bly expressing fluorescence-tagged human LC3B (mRFP-GFP-
LC3B) that enable different stages of autophagy to be visualized
by fluorescence microscopy (35). The appearance of red/green
puncta (yellow when overlapped) indicates autophagosomes,
and as GFP is highly susceptible to the low pH within the lyso-
somes, a “red only” signal indicates autolysosomes. This proc-
ess can be inhibited by hydroxychloroquine (HCQ), which
inhibits autophagy at a late stage by preventing the fusion of
autophagosomes and lysosomes, leading to build-up of yellow
fluorescence. NVP-BEZ235 treatment increased puncta exhibit-
ing a “red only” signal (autophagy flow complete) in KCL22Pon-
Res cells (Figure 5A). This indicates that NVP-BEZ235 induces
autophagy flow, which can be effectively inhibited when com-
bined with HCQ treatment.
Next, we investigated if autophagy induced by NVP-BEZ235
has a protective role. KCL22Pon-Res cells were treated in combi-
nation with chloroquine (CQ)-mediated autophagy inhibition.
While CQ treatment alone did not lead to statistically significant
reduction in colony formation, it statistically significantly
increased the cell death effect of NVP-BEZ235 (P ¼ .04) (Figure
5B). Further combination experiments demonstrated that CQ
and NVP-BEZ235 are synergistic in inhibiting proliferation of
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Figure 3. Sensitivity of ponatinib-resistant cells to allosteric mTORC1
inhibition. An approved oncology drug library was screened against KCL22 and
KCL22Pon-Res cells. Following 72 hours of 1 mM drug treatment, metabolic activ-
ity/proliferation was assessed using resazurin assay. Relative IC50 was calcu-
lated for each drug used, and a comparison was made between KCL22 and
KCL22Pon-Res cells (A) and between KCL22Pon-Res cells cultured in the absence or
presence of 100 nM ponatinib (B).
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Figure 4. Transcriptional changes and levels of apoptosis in ponatinib-resistant cells following treatment with catalytic mTOR inhibitors. A) Schematic diagram dem-
onstrating the activity of allosteric (blue-green) and catalytic (red) mTOR inhibitors. B) KCL22Pon-Res cells were cultured with 150 nM dasatinib, 100 nM ponatinib, 10 nM
rapamycin, 500 nM PI-103, or 100 nM NVP-BEZ235 or untreated (Untr). Phosphorylation of CRKL, RPS6, and 4E-BP1 was measured four hours following drug treatment.
C) KCL22Pon-Res cells were cultured 6 2 mM imatinib, 2 mM nilotinib, 150 nM dasatinib, 100 nM ponatinib, 10 nM rapamycin, or 100 nM NVP-BEZ235, and apoptosis was
measured following 72 hours of drug treatment. Error bars ¼ SD. Three independent experiments were performed. D–G) KCL22Pon-Res cells were cultured 6 100 nM
NVP-BEZ235, alone and in combination with 100 nM ponatinib for 24 hours, and RNA was harvested for RNA-seq. D) The transcriptional response of KCL22Pon-Res cells
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KCL22Pon-Res cells when CQ is used at the 5–20 mM concentration
range (combination index for NVP-BEZ235/CQ concentrations of
50 nM/5 mM, 100 nM/10 mM, 150 nM/15 mM and 200 nM/20 mM
were 0.18, 0.60. 0.50, and 0.52, respectively) (Supplementary
Figure 7, A and B, available online). CRISPR-Cas9 and RNAi tech-
niques were employed to test if the specific inhibition of
autophagy would enhance NVP-BEZ235-induced death. Initially,
ATG7, an E1-like enzyme and essential autophagy gene required
for LC3 lipidation, was targeted using CRISPR-Cas9. ATG7 knock-
down inhibited LC3B-II formation and autophagy, measured by
a decrease in LC3B-II levels and an increase in the autophagy
substrate SQSTM1/p62 (36,37) (Figure 5C), and indeed sensitized
cells to death following NVP-BEZ235-mediated mTOR inhibition
(P ¼ .06) (Figure 5D). Similarly, RNAi-mediated ATG7 knockdown
statistically significantly increased the effect of the NVP-BEZ235
on apoptosis, confirming that autophagy plays a protective role
in KCL22Pon-Res cells following inhibition of mTORC1 (P ¼ .002)
(Figure 5E).
The Effect of Pharmacological Inhibition of Autophagy
and NVP-BEZ235 Treatment In Vivo and in TKI-
Resistant Primary CML Cells
We next tested whether mTOR inhibition can interfere with leu-
kemia initiation when combined with pharmacological autoph-
agy inhibition. KCL22Pon-Res cells were labeled with lentiviral
luciferase and treated ex vivo with NVP-BEZ235, HCQ, and the
combination. Following drug treatment, cells were injected into
NSG mice, which were then monitored weekly by luciferase bio-
imaging. At week 4, there was a marked delay in leukemia
development in mice engrafted with cells treated with the com-
bination (Figure 6A). The combination treatment also statisti-
cally significantly prolonged overall survival of xenografted NSG
mice when compared with NVP-BEZ235 single treatment (P ¼
.01) (Figure 6A).
To test the tolerability and efficacy of this drug combination,
we injected luciferase-expressing KCL22Pon-Res cells into NSG
mice. Following evidence of engraftment, the xenografted mice
were treated for up to five weeks. By week 3, bio-imaging
showed leukemia development in untreated and HCQ-treated
mice (Figure 6B). By five weeks, all untreated and HCQ-treated
mice had to be killed, together with two out of five mice treated
with NVP-BEZ235 alone. Mice showed few signs of toxicity, and
the combination statistically significantly extended the survival
of mice when compared with NVP-BEZ235 single treatment
(median survival NVP-BEZ235 vs NVP-BEZ235þHCQ: 38.5 days
vs 47.0 days, P ¼ .04) (Figure 6B).
Finally, we compared the effect of NVP-BEZ235 in combina-
tion with HCQ with ponatinib on cells derived from the BM of
four patients who had failed to achieve cytogenetic response
following first-, second-, or third-generation TKI treatments
(Supplementary Table 3, available online). Importantly, NVP-
BEZ235 had a greater effect on survival of progenitor cells in
these patients (Figure 6C). HCQ treatment statistically
significantly enhanced the effect of NVP-BEZ235 (NVP-BEZ235
vs NVP-BEZ235þHCQ: 45.0[17.9]% vs 24.0[8.4]%, P ¼ .002). Colony
polymerase chain reaction and fluorescence in situ hybridiza-
tion confirmed that the vast majority of cells were Ph positive
(data not shown). To test the effect of this combination on nor-
mal cells, non-CML cells (derived from patients with Ph-
negative, nonmyeloid hematological malignancies) were
treated with ponatinib, NVP-BEZ235 alone, and in combination
with HCQ, and compared with a cytotoxicity of 10 nM omace-
taxine treatment. This revealed that while omacetaxine sub-
stantially affected the CFC potential of normal progenitor cells,
the combination of NVP-BEZ235 and HCQ had only a minimal
effect (Figure 6D).
Discussion
Despite the promising results in the PACE trial, where ponatinib
induced rapid and durable responses in CP-CML patients, it is
associated with considerable cardiovascular toxicity that may
be dose-dependent. Additionally, a proportion of patients taking
ponatinib already have or will develop BCR-ABL-independent
mechanisms of resistance, and therefore fail ponatinib treat-
ment. Therefore, it is hoped that this patient population that
currently experiences rare response to TKI treatment and very
short survival may share an alternative drug target that can be
inhibited with a novel compound. We, therefore, for the first
time, generated a ponatinib-resistant cell line, which developed
BCR-ABL-independent activation of mTOR. This afforded us a
unique opportunity to search for drugs that are effective against
ponatinib-resistant CML cells. Our screen and subsequent test-
ing of catalytic mTOR inhibitors revealed that NVP-BEZ235 had
increased potency in inhibiting mTORC1 in ponatinib-resistant
cells. This correlated with potent transcriptional response and
induction of apoptosis, in agreement with previous studies
where catalytic mTOR inhibitors, such as OSI-027 and PP242 (or
dual PI3K/mTOR inhibitors, such as PI-103 and NVP-BEZ235),
have been shown to prevent expansion of Ph-positive acute
lymphoblastic leukemia cells in vivo (38), to sensitize CML cells
to nilotinib (39,40), and to be effective in targeting CML cells
in vitro (41,42). Critically, we also showed that NVP-BEZ235 was
more effective than ponatinib against available primary cells
obtained from heavily pretreated TKI-resistant CML patients.
Although further investigation will be required to confirm the
exact mechanism of resistance in each patient (requires opti-
mized protocols for rare BM-aspirated cells), this provides a
rationale for testing catalytic mTOR inhibitors in the clinic for
patients who do not respond to BCR-ABL inhibitors.
A phase I dose-finding study of NVP-BEZ235 is ongoing in
patients with relapsed or refractory acute leukemia
(NCT01756118). Based on a phase I trial in patients with
advanced solid tumors, the recommended dose for NVP-BEZ235
is 300 mg twice daily (BID), which is still expected to inhibit
mTORC1/2 according to pharmacodynamic data (43). However,
recent results from a phase II trial for patients with everolimus-
Figure 4. Continued
to NVP-BEZ235 alone (left) and in combination with ponatinib (right) is represented by Volcano plots (up- and downregulation are indicated by magenta and green,
respectively; light and dark colors correspond to q-value thresholds of 0.05 and 0.01, respectively; statistically nonsignificant changes are colored gray). E) A propor-
tional Venn diagram represents the overlap in statistically significant response (q  0.05) to ponatinib alone (dark blue), NVP-BEZ235 alone (green), and the combina-
tion (light blue) in the KCL22Pon-Res cells. F) A proportional Venn diagram represents the overlap in statistically significant response (q  0.05) to ponatinib in KCL22
cells (red) and NVP-BEZ235 in KCL22Pon-Res cells (green). G) A direct comparison of the transcriptional responses of all 1718 genes to treatment common to both experi-
ments; identical expression is shown by the red line, and the true linear relationship is indicated by the blue line. One independent experiment was performed in
quadruplicate. Untr ¼ untreated.
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Figure 5. Autophagic response following mTOR inhibition in ponatinib-resistant cells. A) KCL22Pon-Res cells expressing mRFP-GFP-LC3 were cultured 6 100 nM NVP-
BEZ235 alone (top panel) or in combination with 10 mM hydroxychloroquine (HCQ; bottom panel). Scale bars ¼ 5 mm. Autophagy flow (top panel) and inhibition of
autophagy flow (bottom panel) was visualized following 24 hours of drug treatment. B) KCL22Pon-Res cells were cultured 6 150 nM dasatinib, 100 nM ponatinib, and 100
nM NVP-BEZ235 with and without chloroquine-mediated autophagy inhibition. Colony forming potential was measured following 72 hours of drug treatment. C–E)
KCL22Pon-Res cells were infected with lentivirus-expressing sgRNA (C and D) or shRNA-targeting (E) ATG7 or empty vector/scrambled (Scr) shRNA as control. Following
knockdown, cells were treated with 100 nM ponatinib (D), 100 nM NVP-BEZ235 (C–E) alone, or in combination with 10 mM HCQ (C). C and E) Stable ATG7 knockdown,
inhibition of autophagy (LC3-II and SQSTM1 levels), and mTORC1 activity were measured in puromycin-selected cells by immunoblot. Colony forming potential (D) or
apoptosis (E) was measured following 72 hours of drug treatment. Error bars ¼ SD. Statistical analysis was performed using the two-tailed Student’s t test. CQ ¼ chloro-
quine; Untr ¼ untreated.
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Figure 6. Sensitivity of xenografted ponatinib-resistant cells and primary chronic phase TKI-resistant chronic myeloid leukemia cells to NVP-BEZ235 and hydroxychlor-
oquine (HCQ)-mediated autophagy inhibition. A) KCL22Pon-Res cells were labeled with firefly luciferase and treated ex vivo with 100 nM NVP-BEZ235, alone and in combi-
nation with 10 mM HCQ. Seventy-two hours following drug treatment, cells were transplanted intravenously into sublethally irradiated NSG mice (four mice per group,
two independent experiments). Thirty minutes after the transplant, the mice were injected with D-luciferin substrate to ensure the success of the transplantation and
the cell viability. Leukemic progression was measured weekly by luciferase bio-imaging (left). Overall survival was monitored by Kaplan-Meier analysis (right). A table
showing the number of mice at risk is shown below the graph. B) Firefly luciferase labeled KCL22Pon-Res cells were transplanted intravenously into NSG mice (five to six
mice per group, two independent experiments). Mice were then treated with NVP-BEZ235 (45 mg/kg, oral gavage), HCQ (60 mg/kg, intraperitoneal injection), and the
combination for up to five weeks. Leukemia progression and overall survival were measured by luciferase bio-imaging (left) and Kaplan-Meier analysis (right),
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resistant pancreatic neuroendocrine tumors (NCT01658436)
show that many patients experience toxicities on 300 mg BID,
although this may also reflect the fragility of the heavily pre-
treated patients with this aggressive cancer (44).
It is clear that the depth of response to TKI is the major
driver for sustained remissions, hence the need to rapidly
reduce overall leukemic cell burden and ideally to reduce the
numbers of BM-located cells (45). We showed that HCQ treat-
ment (a nonspecific autophagy inhibitor that is being tested in
more than 30 active clinical trials [46]) inhibited autophagy flow
and enhanced death following NVP-BEZ235, both in vitro and in
a xenograft model of CML. Importantly, we also showed that
genetic autophagy inhibition sensitized CML cells to death, indi-
cating that the main additive effect of HCQ was due to a block in
the autophagy process, but not off target effect.
A recent phase I trial in patients with advanced solid tumors
and melanoma shows that HCQ is safe and tolerable and has
some antitumor activity when used in combination with
temsirolimus-mediated mTOR inhibition (47). Although our
results on normal blood cells suggest that HCQ and NVP-
BEZ235-mediated mTOR inhibition may be tolerated with
regards to myelosuppression, results from phase I trials are
awaited for different innovative catalytic mTOR inhibitors such
as Gedatolisib, Apitolisib, VS5584, and AZD8055 (all in phase I;
Apitolisib in phase II). The outcome of these studies may deter-
mine the most suitable catalytic mTOR inhibitor (in terms of
efficacy and tolerability) to be taken forward for combination
studies.
Given that the mechanism(s) of resistance to TKIs may vary
from patient to patient, potential limitations of this study
should be considered. First, the in vitro studies of primary CML
cells in response to the catalytic mTOR inhibitor(s) presented
here were confined to a relatively small number of TKI-resistant
CML patients’ samples. Additionally, HCQ is nonspecific
autophagy inhibitor, and development of more specific and/or
more potent autophagy inhibitors might be required to inhibit
autophagy in BM-located cells in CML patients.
We conclude that catalytic mTOR inhibitors may be effective
for patients with BCR-ABL-independent resistance and that
pharmacological autophagy inhibition will further enhance
their efficacy. This is particularly important for this heavily pre-
treated population because treatment options for patients who
fail all currently available TKIs, including ponatinib, are very
limited.
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